APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immunomodulators

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Immunomodulators Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchImmunomodulators Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Immunomodulators Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Immunomodulators Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immunomodulators Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Immunomodulators Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Immunomodulators market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immunomodulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Immunomodulators market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Immunomodulators market include Abbott, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Roche, Eli Lilly and Company, Biogen, Amgen Inc. and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Immunomodulators market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Immunomodulators and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immunomodulators sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Immunomodulators market size, projected growth trends, production technologies, key applications, and end-use industries.

Immunomodulators Segment by Company

Abbott

Johnson & Johnson

Novartis AG

Merck & Co. Inc.

Roche

Eli Lilly and Company

Biogen

Amgen Inc.

Bristol-Myers Squibb Company

Immunomodulators Segment by Type

Immunosuppressant

Immunostimulants

Immunomodulators Segment by Application

HIV

Respiratory

Oncology

Others

Immunomodulators Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Immunomodulators status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Immunomodulators market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Immunomodulators significant trends, drivers, influence factors in global and regions.

6. To analyze Immunomodulators competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immunomodulators market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immunomodulators and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immunomodulators.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Immunomodulators market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immunomodulators industry.

Chapter 3: Detailed analysis of Immunomodulators manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Immunomodulators in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Immunomodulators in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Immunomodulators Industry Trends Table 2. Immunomodulators Industry Drivers Table 3. Immunomodulators Industry Opportunities and Challenges Table 4. Immunomodulators Industry Restraints Table 5. Global Immunomodulators Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Immunomodulators Revenue Share by Company (2021-2026) Table 7. Global Immunomodulators Sales Volume by Company (k units) & (2021-2026) Table 8. Global Immunomodulators Sales Volume Share by Company (2021-2026) Table 9. Global Immunomodulators Average Price (US$/unit) of Company (2021-2026) Table 10. Global Immunomodulators Company Ranking, (2024-2026) & (USD Million) Table 11. Global Immunomodulators Key Company Manufacturing Base & Headquarters Table 12. Global Immunomodulators Company, Product Type & Application Table 13. Global Immunomodulators Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Immunomodulators by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Immunosuppressant Table 18. Significant Companies of Immunostimulants Table 19. Global Immunomodulators Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Immunomodulators Sales Volume by Type (2021-2026) & (k units) Table 21. Global Immunomodulators Sales Volume by Type (2027-2032) & (k units) Table 22. Global Immunomodulators Sales Volume Share by Type (2021-2026) Table 23. Global Immunomodulators Sales Volume Share by Type (2027-2032) Table 24. Global Immunomodulators Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Immunomodulators Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Immunomodulators Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Immunomodulators Sales Value Share by Type (2021-2026) Table 28. Global Immunomodulators Sales Value Share by Type (2027-2032) Table 29. Significant Companies of HIV Table 30. Significant Companies of Respiratory Table 31. Significant Companies of Oncology Table 32. Significant Companies of Others Table 33. Global Immunomodulators Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Immunomodulators Sales Volume by Application (2021-2026) & (k units) Table 35. Global Immunomodulators Sales Volume by Application (2027-2032) & (k units) Table 36. Global Immunomodulators Sales Volume Share by Application (2021-2026) Table 37. Global Immunomodulators Sales Volume Share by Application (2027-2032) Table 38. Global Immunomodulators Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Immunomodulators Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Immunomodulators Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Immunomodulators Sales Value Share by Application (2021-2026) Table 42. Global Immunomodulators Sales Value Share by Application (2027-2032) Table 43. Global Immunomodulators Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Immunomodulators Sales by Region (2021-2026) & (k units) Table 45. Global Immunomodulators Sales Market Share by Region (2021-2026) Table 46. Global Immunomodulators Sales by Region (2027-2032) & (k units) Table 47. Global Immunomodulators Sales Market Share by Region (2027-2032) Table 48. Global Immunomodulators Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Immunomodulators Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Immunomodulators Sales Value Share by Region (2021-2026) Table 51. Global Immunomodulators Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Immunomodulators Sales Value Share by Region (2027-2032) Table 53. Global Immunomodulators Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Immunomodulators Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Immunomodulators Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Immunomodulators Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Immunomodulators Sales by Country (2021-2026) & (k units) Table 58. Global Immunomodulators Sales Market Share by Country (2021-2026) Table 59. Global Immunomodulators Sales by Country (2027-2032) & (k units) Table 60. Global Immunomodulators Sales Market Share by Country (2027-2032) Table 61. Global Immunomodulators Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Immunomodulators Sales Value Market Share by Country (2021-2026) Table 63. Global Immunomodulators Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Immunomodulators Sales Value Market Share by Country (2027-2032) Table 65. Abbott Company Information Table 66. Abbott Business Overview Table 67. Abbott Immunomodulators Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Abbott Immunomodulators Product Portfolio Table 69. Abbott Recent Development Table 70. Johnson & Johnson Company Information Table 71. Johnson & Johnson Business Overview Table 72. Johnson & Johnson Immunomodulators Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Johnson & Johnson Immunomodulators Product Portfolio Table 74. Johnson & Johnson Recent Development Table 75. Novartis AG Company Information Table 76. Novartis AG Business Overview Table 77. Novartis AG Immunomodulators Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Novartis AG Immunomodulators Product Portfolio Table 79. Novartis AG Recent Development Table 80. Merck & Co. Inc. Company Information Table 81. Merck & Co. Inc. Business Overview Table 82. Merck & Co. Inc. Immunomodulators Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Merck & Co. Inc. Immunomodulators Product Portfolio Table 84. Merck & Co. Inc. Recent Development Table 85. Roche Company Information Table 86. Roche Business Overview Table 87. Roche Immunomodulators Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Roche Immunomodulators Product Portfolio Table 89. Roche Recent Development Table 90. Eli Lilly and Company Company Information Table 91. Eli Lilly and Company Business Overview Table 92. Eli Lilly and Company Immunomodulators Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Eli Lilly and Company Immunomodulators Product Portfolio Table 94. Eli Lilly and Company Recent Development Table 95. Biogen Company Information Table 96. Biogen Business Overview Table 97. Biogen Immunomodulators Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Biogen Immunomodulators Product Portfolio Table 99. Biogen Recent Development Table 100. Amgen Inc. Company Information Table 101. Amgen Inc. Business Overview Table 102. Amgen Inc. Immunomodulators Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Amgen Inc. Immunomodulators Product Portfolio Table 104. Amgen Inc. Recent Development Table 105. Bristol-Myers Squibb Company Company Information Table 106. Bristol-Myers Squibb Company Business Overview Table 107. Bristol-Myers Squibb Company Immunomodulators Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Bristol-Myers Squibb Company Immunomodulators Product Portfolio Table 109. Bristol-Myers Squibb Company Recent Development Table 110. Key Raw Materials Table 111. Raw Materials Key Suppliers Table 112. Immunomodulators Distributors List Table 113. Immunomodulators Customers List Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Immunomodulators Product Image Figure 2. Global Immunomodulators Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 4. Global Immunomodulators Sales (2021-2032) & (k units) Figure 5. Global Immunomodulators Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Immunomodulators Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Immunosuppressant Image Figure 10. Immunostimulants Image Figure 11. Global Immunomodulators Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Immunomodulators Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Immunomodulators Sales Volume Share by Type (2021-2032) Figure 14. Global Immunomodulators Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Immunomodulators Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Immunomodulators Sales Value Share by Type (2021-2032) Figure 17. HIV Image Figure 18. Respiratory Image Figure 19. Oncology Image Figure 20. Others Image Figure 21. Global Immunomodulators Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Immunomodulators Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Immunomodulators Sales Volume Share by Application (2021-2032) Figure 24. Global Immunomodulators Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Immunomodulators Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Immunomodulators Sales Value Share by Application (2021-2032) Figure 27. Global Immunomodulators Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Immunomodulators Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Immunomodulators Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Immunomodulators Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 32. North America Immunomodulators Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Immunomodulators Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Immunomodulators Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 38. South America Immunomodulators Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Immunomodulators Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Immunomodulators Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Immunomodulators Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Immunomodulators Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Immunomodulators Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Immunomodulators Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Immunomodulators Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Immunosuppressant
  • Immunostimulants
Applications
  • HIV
  • Respiratory
  • Oncology
  • Others
Companies covered
  • Abbott
  • Johnson & Johnson
  • Novartis AG
  • Merck & Co. Inc.
  • Roche
  • Eli Lilly and Company
  • Biogen
  • Amgen Inc.
  • Bristol-Myers Squibb Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Immunomodulators Sales Value (2021-2032)
  4. 1.2.2 Global Immunomodulators Sales Volume (2021-2032)
  5. 1.2.3 Global Immunomodulators Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Immunomodulators Market Dynamics
  1. 2.1 Immunomodulators Industry Trends
  2. 2.2 Immunomodulators Industry Drivers
  3. 2.3 Immunomodulators Industry Opportunities and Challenges
  4. 2.4 Immunomodulators Industry Restraints
3 Immunomodulators Market by Company
  1. 3.1 Global Immunomodulators Company Revenue Ranking in 2025
  2. 3.2 Global Immunomodulators Revenue by Company (2021-2026)
  3. 3.3 Global Immunomodulators Sales Volume by Company (2021-2026)
  4. 3.4 Global Immunomodulators Average Price by Company (2021-2026)
  5. 3.5 Global Immunomodulators Company Ranking (2024-2026)
  6. 3.6 Global Immunomodulators Company Manufacturing Base and Headquarters
  7. 3.7 Global Immunomodulators Company Product Type and Application
  8. 3.8 Global Immunomodulators Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Immunomodulators Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Immunomodulators Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Immunomodulators Market by Type
  1. 4.1 Immunomodulators Type Introduction
  2. 4.1.1 Immunosuppressant
  3. 4.1.2 Immunostimulants
  4. 4.2 Global Immunomodulators Sales Volume by Type
  5. 4.2.1 Global Immunomodulators Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Immunomodulators Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Immunomodulators Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Immunomodulators Sales Value by Type
  9. 4.3.1 Global Immunomodulators Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Immunomodulators Sales Value by Type (2021-2032)
  11. 4.3.3 Global Immunomodulators Sales Value Share by Type (2021-2032)
5 Immunomodulators Market by Application
  1. 5.1 Immunomodulators Application Introduction
  2. 5.1.1 HIV
  3. 5.1.2 Respiratory
  4. 5.1.3 Oncology
  5. 5.1.4 Others
  6. 5.2 Global Immunomodulators Sales Volume by Application
  7. 5.2.1 Global Immunomodulators Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Immunomodulators Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Immunomodulators Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Immunomodulators Sales Value by Application
  11. 5.3.1 Global Immunomodulators Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Immunomodulators Sales Value by Application (2021-2032)
  13. 5.3.3 Global Immunomodulators Sales Value Share by Application (2021-2032)
6 Immunomodulators Regional Sales and Value Analysis
  1. 6.1 Global Immunomodulators Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Immunomodulators Sales by Region (2021-2032)
  3. 6.2.1 Global Immunomodulators Sales by Region: 2021-2026
  4. 6.2.2 Global Immunomodulators Sales by Region (2027-2032)
  5. 6.3 Global Immunomodulators Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Immunomodulators Sales Value by Region (2021-2032)
  7. 6.4.1 Global Immunomodulators Sales Value by Region: 2021-2026
  8. 6.4.2 Global Immunomodulators Sales Value by Region (2027-2032)
  9. 6.5 Global Immunomodulators Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Immunomodulators Sales Value (2021-2032)
  12. 6.6.2 North America Immunomodulators Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Immunomodulators Sales Value (2021-2032)
  15. 6.7.2 Europe Immunomodulators Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Immunomodulators Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Immunomodulators Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Immunomodulators Sales Value (2021-2032)
  21. 6.9.2 South America Immunomodulators Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Immunomodulators Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Immunomodulators Sales Value Share by Country, 2025 VS 2032
7 Immunomodulators Country-level Sales and Value Analysis
  1. 7.1 Global Immunomodulators Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Immunomodulators Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Immunomodulators Sales by Country (2021-2032)
  4. 7.3.1 Global Immunomodulators Sales by Country (2021-2026)
  5. 7.3.2 Global Immunomodulators Sales by Country (2027-2032)
  6. 7.4 Global Immunomodulators Sales Value by Country (2021-2032)
  7. 7.4.1 Global Immunomodulators Sales Value by Country (2021-2026)
  8. 7.4.2 Global Immunomodulators Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Immunomodulators Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Immunomodulators Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Immunomodulators Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Immunomodulators Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Immunomodulators Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Immunomodulators Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Immunomodulators Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Immunomodulators Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Immunomodulators Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Immunomodulators Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Immunomodulators Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Immunomodulators Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Immunomodulators Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Immunomodulators Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Immunomodulators Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Immunomodulators Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Immunomodulators Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Immunomodulators Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Immunomodulators Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Immunomodulators Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Immunomodulators Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Immunomodulators Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Immunomodulators Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Immunomodulators Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Immunomodulators Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Immunomodulators Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Immunomodulators Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Immunomodulators Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Immunomodulators Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Immunomodulators Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Immunomodulators Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Immunomodulators Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Immunomodulators Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Immunomodulators Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Immunomodulators Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Immunomodulators Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Immunomodulators Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Immunomodulators Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Immunomodulators Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Immunomodulators Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Immunomodulators Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Immunomodulators Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Immunomodulators Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Immunomodulators Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Immunomodulators Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Immunomodulators Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Immunomodulators Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Immunomodulators Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Immunomodulators Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Immunomodulators Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Immunomodulators Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Immunomodulators Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Immunomodulators Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Immunomodulators Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Immunomodulators Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Immunomodulators Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Immunomodulators Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Immunomodulators Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Immunomodulators Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Immunomodulators Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Immunomodulators Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Immunomodulators Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Immunomodulators Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Immunomodulators Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Immunomodulators Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Immunomodulators Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Immunomodulators Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Immunomodulators Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Immunomodulators Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Immunomodulators Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Immunomodulators Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Immunomodulators Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Immunomodulators Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Immunomodulators Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Immunomodulators Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Immunomodulators Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Immunomodulators Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Immunomodulators Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Immunomodulators Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Immunomodulators Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Immunomodulators Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Immunomodulators Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Immunomodulators Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Immunomodulators Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Immunomodulators Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Immunomodulators Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Immunomodulators Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Immunomodulators Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis AG
  14. 8.3.1 Novartis AG Company Information
  15. 8.3.2 Novartis AG Business Overview
  16. 8.3.3 Novartis AG Immunomodulators Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis AG Immunomodulators Product Portfolio
  18. 8.3.5 Novartis AG Recent Developments
  19. 8.4 Merck & Co. Inc.
  20. 8.4.1 Merck & Co. Inc. Company Information
  21. 8.4.2 Merck & Co. Inc. Business Overview
  22. 8.4.3 Merck & Co. Inc. Immunomodulators Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck & Co. Inc. Immunomodulators Product Portfolio
  24. 8.4.5 Merck & Co. Inc. Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Immunomodulators Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Roche Immunomodulators Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Eli Lilly and Company
  32. 8.6.1 Eli Lilly and Company Company Information
  33. 8.6.2 Eli Lilly and Company Business Overview
  34. 8.6.3 Eli Lilly and Company Immunomodulators Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly and Company Immunomodulators Product Portfolio
  36. 8.6.5 Eli Lilly and Company Recent Developments
  37. 8.7 Biogen
  38. 8.7.1 Biogen Company Information
  39. 8.7.2 Biogen Business Overview
  40. 8.7.3 Biogen Immunomodulators Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biogen Immunomodulators Product Portfolio
  42. 8.7.5 Biogen Recent Developments
  43. 8.8 Amgen Inc.
  44. 8.8.1 Amgen Inc. Company Information
  45. 8.8.2 Amgen Inc. Business Overview
  46. 8.8.3 Amgen Inc. Immunomodulators Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Inc. Immunomodulators Product Portfolio
  48. 8.8.5 Amgen Inc. Recent Developments
  49. 8.9 Bristol-Myers Squibb Company
  50. 8.9.1 Bristol-Myers Squibb Company Company Information
  51. 8.9.2 Bristol-Myers Squibb Company Business Overview
  52. 8.9.3 Bristol-Myers Squibb Company Immunomodulators Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Company Immunomodulators Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Company Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Immunomodulators Value Chain Analysis
  2. 9.1.1 Immunomodulators Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Immunomodulators Sales Mode & Process
  6. 9.2 Immunomodulators Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Immunomodulators Distributors
  9. 9.2.3 Immunomodulators Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst